Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHF5993 HFA-152a versus HFA-134a safety study in adults with asthma
ISRCTN17142179Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Nov 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, triple-blind trial of beclomethasone dipropionate, formoterol and glycopyrronium in asthma (2 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Potential for bronchoconstriction at Day 1. Started Nov 2023; status: completed.
02
Drugs
beclomethasone dipropionateformoterolglycopyrronium
03
Conditions
asthma
Beyond the preview
Go deeper on ISRCTN17142179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17142179.